An observational study in Glaucoma, sponsored by Mario Stirpe. Enrolling by invitation at 19 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Mario Stirpe · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.
Among the 53 studies in Glaucoma with a site in Italy, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, and was the 47th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:
Laboratoires Thea · Sites in Italy
Ages 18+
Centervue SpA · Sites in Italy
Ages 40–90
Fondazione G.B. Bietti, IRCCS · Sites in Italy
Ages 18+
Mario Stirpe · Sites in Italy
Ages 18+ · Healthy volunteers
Association for Innovation and Biomedical Research on Light and Image · Sites in Italy, Germany, Spain and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 7 · Phase 4 14
First in 1993; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is close to the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 64 across the 39 interventional studies, 200 across the 13 observational. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 53 have an industry lead sponsor. The 10 most frequent:
Mario Stirpe is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Mario Stirpe has 2 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07006194Università degli Studi 'G. d'Annunzio' Chieti e PescaraNicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP) | 2026-12-31 |
| NCT07206628Laboratoires TheaReal-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP® | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Glaucoma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation.
The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation. Every patients will be followed for 24 months.
Secondary aims of the study are:
Glaucoma patients attending the hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnosis of primary or secondary open-angle glaucoma according to the diagnostic criteria of 4th edition of the European Glaucoma Society Guidelines.
IOP
IOP values before and after 24 months of XEN63 implant.
Time frame: up to 2 years
Number of hypotensive eye drops
Number of hypotensive eye drops
Time frame: up to 2 years
IOP
IOP values before and after 12 months of XEN63 implant.
Time frame: From enrollment to 12 months after surgery
Number of hypotensive eye drops
Number of hypotensive eye drops before and after 12 months of XEN63 implant
Time frame: From enrollment to 12 months after surgery
Complications
\- Type and number of intraoperative and postoperative complications.
Time frame: up to 2 years
Quality of life after XEN63 implant
Quality of life questionnaire (National Eye Institute Visual Function Questionnaire-25) scores over time. The minimum value is 0, the maximum value is 100. Higher score means a better outcome.
Time frame: up to 2 years
Surgical tecnique
Data on surgical technique: site of XEN63 implant
Time frame: during the intervention/procedure/surgery
Post operative management
Post operative treatment: type of steroids used
Time frame: up to 2 years
Post operative needling
Number of needling
Time frame: up to 2 years
Surgical revision
Number of surgical revision
Time frame: up to 2 years
Glaucoma Symptom Scale
A brief symptom survey specific for persons with glaucoma. This score is transformed to a 0 to 100 scale, with 0 representing presence of a very bothersome problem and 100 representing absence of a problem.
Time frame: up to 2 years
Surgical technique
Data on surgical technique: type of viscoelastic used
Time frame: during the intervention/procedure/surgery
Post operative management
Type and number of hypotensive drops used to control IOP after surgery if needed.
Time frame: up to 2 years
Plan to share: No
Started Nov 2024 (actual). Primary completion is estimated for Dec 2030, 73 months after the start.
Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 73 months is above that.
Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mario Stirpe